Hansa Biopharma AB (HNSBF)
2.90
0.00 (0.00%)
USD |
OTCM |
Feb 26, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 289.23M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -3.33% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 10.42 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -11.10 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 92.88% |
Profile
| Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden. |
| URL | http://www.hansabiopharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Skane |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 23, 2026 (est.) |
| Last Earnings Release | Feb. 11, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden. |
| URL | http://www.hansabiopharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Skane |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Apr. 23, 2026 (est.) |
| Last Earnings Release | Feb. 11, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |